Related Experiment Video
Updated: Jun 12, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.6K
2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid
Hack-Lyoung Kim1, Jung-Joon Cha2, Sang-Hak Lee3
1Division of Cardiology, Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
Journal of Lipid and Atherosclerosis
|June 10, 2025
Summary
Inclisiran and bempedoic acid are novel non-statin therapies that effectively lower LDL cholesterol. Inclisiran reduces LDL-C by 50%, while bempedoic acid offers a 17-21% reduction with fewer muscle side effects.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Inclisiran and bempedoic acid are emerging non-statin lipid-lowering agents approved in the US and Europe.
- These agents offer alternative or adjunctive strategies for managing hyperlipidemia, particularly for patients with statin intolerance or contraindications.
Purpose of the Study:
- To review the mechanisms of action, efficacy, safety, and clinical applications of inclisiran and bempedoic acid.
- To compare their roles in primary and secondary cardiovascular prevention.
Main Methods:
- Inclisiran: Small interfering RNA targeting PCSK9 mRNA, delivered via lipid nanoparticles for hepatic uptake.
- Bempedoic acid: Oral inhibitor of adenosine triphosphate-citrate lyase (ACL), reducing hepatic cholesterol synthesis.
Main Results:
- Inclisiran demonstrated a 50% reduction in LDL-C in Phase 3 trials with an acceptable safety profile; clinical outcome data are pending.
- Bempedoic acid lowered LDL-C by 17%-21% and showed clinical benefit in statin-intolerant patients, with a modest increase in gout and cholelithiasis incidence.
Conclusions:
- Inclisiran and bempedoic acid represent valuable additions to the lipid-lowering armamentarium, offering distinct mechanisms and efficacy profiles.
- They are recommended as non-first-line agents for cardiovascular prevention, often after or in combination with statins, considering patient-specific factors and tolerability.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
581
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
581
01:23Dipeptidyl Peptidase 4 Inhibitors
177
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
177
01:26Atherosclerosis III: Management
2
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
155
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
155
01:21Drugs for Treatment of Constipation-Predominant IBS
140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
483
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
483